entertainment -WSS

entertainment

author：hotspot 2025-09-30 13:13:51 - browse：63196

Drugmakers already bet big on mRNA for cancer. Now President Biden is going in, too? Anna Moneymaker/Getty Images

WASHINGTON — President Biden’s fledgling health agency, designed to accelerate under-funded research, just set its sights on one of the hottest areas of medicine — and one where the drug industry has a multibillion-dollar head start.

The White House announced Wednesday that the Advanced Research Projects Agency for Health would bankroll a $24 million project by Emory University to build messenger RNA platforms to target “cancer and other diseases,” investing in the technology behind the U.S.’s most commonly used vaccines for Covid-19.

The administration touted the news of CUREIT as the latest in Biden’s longtime mission to rein in cancer deaths, the Cancer Moonshot. But by using mRNA to treat cancer, ARPA-H is wading into a field that has advanced in fits and starts — and whose industry leaders have already spent multiples of the program’s entire budget into their own research. Moderna and BioNTech, massively profitable companies that have sold more than $80 billion worth of Covid-19 vaccines combined, have singled out oncology as the next big application for mRNA and invested accordingly.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： STAT Wunderkinds: Ruey Hu's digital tools for parsing research

WSS

The FDA weighs the risks of candy

Meta's Zuckerberg and Chan on track to put $50 billion into science

WHO may add ‘noma' to its list of neglected tropical diseases

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Telehealth options flood the market as retailers push virtual care

focus

entertainment

hotspot

At least 13 dead in Texas as scorching temps continue

Telehealth options flood the market as retailers push virtual care

Affirmative action in medical school literally saved lives

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Medicare proposal to cover medical devices draws a mixed reaction

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Moonlake's readout produced a cash windfall. Risks remain

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

United colonoscopy coverage change 'may cost lives,' doctors say

Emergency medicine has repudiated 'excited delirium.' Now what?

focus

Chimpanzees, like humans and whales, get menopause: Study

First Opinion Podcast: How to protect health care in times of war

When prostate cancer spreads, where it goes matters

Traditional Chinese medicine benefits explored in new JAMA study

It's time to retire 'poor historian' from clinicians' vocabularies

Glen Campbell's doctor discusses his public struggle with Alzheimer's

focus

explore

focus

focus